Abstract Details

Title Unraveling the Neurological Puzzle: From Multiple Sclerosis to Neuromyelitis Optica

Topic Multiple Sclerosis

Presentation(s) P2 - Poster Session 2 (2:45 PM-3:45 PM)

Poster/Presentation
Number 090

Objective The purpose of this systematic review is to examine the clinical characteristics of MS patients who later developed NMO, with an emphasis on the parallels and differences in presentation, diagnostic standards, and therapeutic modalities.

Background The autoimmune neurological disorders Multiple Sclerosis (MS) and Neuromyelitis Optica (NMO) have different clinical and pathological characteristics. Evidence does, however, indicate that some MS patients may go on to acquire NMO.

Design/Methods Public databases (PubMed, Scopus, Cochrane, Embase, and Web of Science) were searched extensively for relevant material. After being extracted, the data were categorized. The collected information was transferred into standardized Google spreadsheets and analyzed to assess the clinical characteristics of MS to NMO patients.

Results Twenty-three studies comprising 1305 patients were included in the final analysis. Patients who went from MS to NMO showed more prominent MRI abnormalities, more frequent relapses, and a larger progression of impairment. More specifically, compared to 653 individuals with isolated MS, 914 transitioned patients had exacerbations at a rate of more than two episodes annually. Furthermore, compared to 228 individuals with isolated MS, 1044 transitioned patients had longitudinally severe spinal cord lesions. Additionally, 228 patients with isolated MS received disease-modifying medications tailored to their circumstances, whereas 653 transitioning patients received immunosuppressive medicines targeting NMO.

Conclusions The clinical characteristics of patients who were initially diagnosed with MS but later developed NMO are thoroughly analyzed in this systematic review. When we compared it to isolated MS or NMO patients, it demonstrated variations in presentation, diagnostic standards, and therapeutic approaches. Our results highlight how important it is to diagnose NMO in MS patients as soon as possible in order to allow doctors to better tailor treatment plans and enhance overall clinical outcomes.

Authors/Disclosures
Ahmad A. Alkabi, MD PRESENTER	Mr. Alkabi has nothing to disclose.
Rula A. AlShimi (JUST)	Ms. AlShimi has nothing to disclose.
Abdel Qader Abu-Salih, MD	Mr. Abu-Salih has nothing to disclose.
Mohammad Al-Bdour	Mohammad Al-Bdour has nothing to disclose.
Ramez Odat	No disclosure on file

��ɫ��

��ɫ��